carbon monoxide has been researched along with Dermatoses in 8 studies
Carbon Monoxide: Carbon monoxide (CO). A poisonous colorless, odorless, tasteless gas. It combines with hemoglobin to form carboxyhemoglobin, which has no oxygen carrying capacity. The resultant oxygen deprivation causes headache, dizziness, decreased pulse and respiratory rates, unconsciousness, and death. (From Merck Index, 11th ed)
carbon monoxide : A one-carbon compound in which the carbon is joined only to a single oxygen. It is a colourless, odourless, tasteless, toxic gas.
Excerpt | Relevance | Reference |
---|---|---|
"Patients with SSc meeting the ACR/EULAR systemic sclerosis classification criteria with diffuse cutaneous SSc (dcSSc) subset per LeRoy criteria, and a disease duration of less than or equal to 18 months will be randomized to placebo or riociguat 0." | 2.84 | RISE-SSc: Riociguat in diffuse cutaneous systemic sclerosis. ( Allanore, Y; de Oliveira Pena, J; Denton, C; Distler, O; Khanna, D; Matucci-Cerinic, M; Pope, J, 2017) |
"Carbon monoxide (CO) is an important gaseous signaling molecule." | 1.62 | Red Light-Triggered Intracellular Carbon Monoxide Release Enables Selective Eradication of MRSA Infection. ( Cheng, J; Gan, G; Gao, L; Hu, J; Shen, Z; Zhang, G, 2021) |
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 5 (62.50) | 18.7374 |
1990's | 1 (12.50) | 18.2507 |
2000's | 0 (0.00) | 29.6817 |
2010's | 1 (12.50) | 24.3611 |
2020's | 1 (12.50) | 2.80 |
Authors | Studies |
---|---|
Cheng, J | 1 |
Gan, G | 1 |
Shen, Z | 1 |
Gao, L | 1 |
Zhang, G | 1 |
Hu, J | 1 |
Distler, O | 1 |
Pope, J | 1 |
Denton, C | 1 |
Allanore, Y | 1 |
Matucci-Cerinic, M | 1 |
de Oliveira Pena, J | 1 |
Khanna, D | 1 |
MIGNOLET, F | 1 |
ROBERTSON, EE | 1 |
Rahier, S | 1 |
Piérard-Franchimont, C | 1 |
Piérard, GE | 1 |
Gagnon, L | 1 |
Blouin, A | 1 |
Cormier, Y | 1 |
Rye, WA | 1 |
Bolot, JF | 1 |
Bernard, JP | 1 |
Wiesendanger, MT | 1 |
Biron, A | 1 |
Bertoye, A | 1 |
Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
---|---|---|---|---|---|---|---|
A Randomized, Double-Blind, Placebo-Controlled Phase II Study to Investigate the Efficacy and Safety of Riociguat in Patients With Diffuse Cutaneous Systemic Sclerosis (dcSSc)[NCT02283762] | Phase 2 | 121 participants (Actual) | Interventional | 2015-01-15 | Completed | ||
[information is prepared from clinicaltrials.gov, extracted Sep-2024] |
Negative change in FVC percent predicted indicates worsening. (NCT02283762)
Timeframe: Baseline to week 52
Intervention | FVC percent predicted (Mean) |
---|---|
Riociguat (Adempas, BAY63-2521) | -2.376 |
Placebo | -2.945 |
The mRSS is a validated physical examination method for estimating skin thickness. It correlates with biopsy measures of collagen in the dermis and reflects prognosis and visceral involvement, especially in early disease. It is scored on 0 (normal) to 3+ (severe induration) ordinal scales over 17 body areas, with a maximum score of 51 (higher score means worse situation) and is used to categorize severity of SSc. A decrease in the mean change of mRSS shows mRSS improved. (NCT02283762)
Timeframe: Baseline to week 52
Intervention | score on a scale (Mean) |
---|---|
Riociguat (Adempas, BAY63-2521) | -2.088 |
Placebo | -0.769 |
The HAQ-DI is a composite measure from which a 'Standard Disability Index' score can be computed to assess a patient's disability level. Generally, a score of 0-1 represents mild to moderate difficulty, 1-2 moderate to severe disability and 2-3 severe to very severe disability. The HAQ-DI comprises 20 items that assess patient abilities across 8 functional activities: dressing, rising, eating, walking, hygiene, reach, grip, and usual activities. Each item is rated on a 4-point scale: 0=Without ANY difficulty, 1=With SOME difficulty, 2=With MUCH difficulty, 3=UNABLE to do. The 8 scores of the 8 sections are summed and divided by 8. In the event that one section is not completed by a subject then the summed score would be divided by 7. The final overall HAQ-DI score ranges from 0 to 3 and positive change indicates worse health-related quality of life (HRQoL). (NCT02283762)
Timeframe: Baseline to week 52
Intervention | score on a scale (Mean) | |
---|---|---|
Baseline | Change from baseline | |
Placebo | 0.693 | 0.127 |
Riociguat (Adempas, BAY63-2521) | 0.888 | 0.054 |
The patient's global assessments (a self-report) quantified the overall disease activity or severity of SSc, with scores ranging from 0 (good) to 10 (worse). Positive change in the patient's global assessments score indicates worsening. (NCT02283762)
Timeframe: Baseline to week 52
Intervention | score on a scale (Mean) | |
---|---|---|
Baseline | Change from baseline | |
Placebo | 3.770 | -0.022 |
Riociguat (Adempas, BAY63-2521) | 3.933 | 0.689 |
The physician's global assessments (reported by the physician) quantified the overall disease activity or severity of SSc, with scores ranging from 0 (good) to 10 (worse). Positive change in the physician's global assessments score indicates worsening. (NCT02283762)
Timeframe: Baseline to week 52
Intervention | score on a scale (Mean) | |
---|---|---|
Baseline | Change from baseline | |
Placebo | 4.016 | -0.745 |
Riociguat (Adempas, BAY63-2521) | 4.333 | -0.067 |
CRISS forms a composite response index consisting of SSc-related organ involvement and the following five variables: mRSS, FVC percent predicted, physician's and patient's global assessments, and HAQ-DI score (from SHAQ patient-reported outcome). The resulting index is a 2-step process that captures clinically meaningful worsening of internal organ involvement and the core variables that show change. Patients for whom the predicted CRISS probability was ≥ 0.60 were considered improved, while patients for whom the predicted probability was < 0.60 were considered not improved. (NCT02283762)
Timeframe: Week 52
Intervention | Participants (Count of Participants) | |
---|---|---|
CRISS probability ≥ 0.60 | CRISS probability < 0.60 | |
Placebo | 11 | 50 |
Riociguat (Adempas, BAY63-2521) | 11 | 49 |
1 review available for carbon monoxide and Dermatoses
Article | Year |
---|---|
[The skin of tobacco smokers].
Topics: Aging; Carbon Monoxide; Humans; Irritants; Leukoplakia, Oral; Nicotine; Skin Diseases; Skin Physiolo | 1996 |
1 trial available for carbon monoxide and Dermatoses
Article | Year |
---|---|
RISE-SSc: Riociguat in diffuse cutaneous systemic sclerosis.
Topics: Carbon Monoxide; Dose-Response Relationship, Drug; Double-Blind Method; Enzyme Activators; Female; H | 2017 |
6 other studies available for carbon monoxide and Dermatoses
Article | Year |
---|---|
Red Light-Triggered Intracellular Carbon Monoxide Release Enables Selective Eradication of MRSA Infection.
Topics: Animals; Anti-Bacterial Agents; Carbon Monoxide; Drug Liberation; Escherichia coli; Flavanones; Ligh | 2021 |
Suggestion on the prevention of chronic carbon monoxide poisoning.
Topics: Carbon Monoxide; Humans; Occupational Diseases; Skin; Skin Diseases | 1948 |
Skin lesions in organic brain disease.
Topics: Brain; Brain Diseases; Brain Neoplasms; Carbon Monoxide; Carbon Monoxide Poisoning; Cerebral Hemorrh | 1953 |
Bronchocutaneous fistula in dogs: influence of fistula size and ventilatory mode on airleak.
Topics: Animals; Bronchial Fistula; Carbon Monoxide; Dogs; Fistula; High-Frequency Jet Ventilation; Oxygen; | 1989 |
Human responses to isocyanate exposure.
Topics: Aerosols; Animals; Carbon Monoxide; Cyanates; Environmental Exposure; Eye Diseases; Hot Temperature; | 1973 |
[Study of carbon monoxide transfer in the course of prolonged hyperbaric oxygen therapy given at intermittent sessions].
Topics: Adult; Aged; Apnea; Bone Diseases; Carbon Monoxide; Female; Humans; Hyperbaric Oxygenation; Lung; Ma | 1970 |